Fusion Antibodies teams with Analytics Engines on machine learning, AI platform

GloballData, artificial intelligence (AI)
Fusion Antibodies is partnering with Analytics Engines to incorporate machine learning and AI into its CDRx humanization platform. (GlobalData)

U.K.-based CRO Fusion Antibodies is partnering with Analytics Engines to incorporate machine learning and artificial intelligence into its CDRx humanization platform.

The platform can perform multiple virtual experiments using machine learning and AI with panels of selected antibodies. The goal of the partnership is to boost Fusion’s platform in order for the company to meet its goal of reducing development costs and increasing the speed of clinical timelines.

“We want to keep differentiating our product to make sure it’s the best humanization platform in the world,” Paul Kerr, Fusion’s chief executive, said in a statement. “Collaborating with Analytics Engines will allow us to drive our quality and add more certainty and manufacturability to the products.”


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

The company’s CDRx platform builds on traditional clinical data repository (CDR) grafting techniques by in silico grafting parental CDRs into mature human antibody frameworks. It can screen a database of about 100,000 use antibody sequences as well as generate full-length humanized antibodies that can be refined to a level that further resembles human antibodies.

“Using our expertise in machine learning and AI, Fusion Antibodies will be able to create ML models to continually improve their antibody humanization process,” Aislinn Rice, Ph.D., Analytics Engines’ CEO, said in a statement.

Suggested Articles

WIRB-Copernicus Group has added two new executives to its roster as it expands its Global Research Network of investigative sites.

Incoming FDA Commissioner Ned Sharpless used his first official talk to ensure we all know he’s not looking to tear up Scott Gottlieb’s legacy.

Charles River Labs and the CHDI Foundation have signed a five-year extension for their Huntington’s disease work.